{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T01:30:09Z","timestamp":1772155809445,"version":"3.50.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T00:00:00Z","timestamp":1712102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Wellcome Trust & The Royal Society","award":["202397\/Z\/16\/Z"],"award-info":[{"award-number":["202397\/Z\/16\/Z"]}]},{"name":"Wellcome Trust Clinical Research Career Development","award":["224625\/Z\/21\/Z"],"award-info":[{"award-number":["224625\/Z\/21\/Z"]}]},{"DOI":"10.13039\/100007197","name":"United States Public Health Service","doi-asserted-by":"publisher","award":["NIMH MH57440"],"award-info":[{"award-number":["NIMH MH57440"]}],"id":[{"id":"10.13039\/100007197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Hypothesis<\/jats:title>\n                    <jats:p>Animal models indicate GABAergic dysfunction in the development of psychosis, and that benzodiazepine (BDZ) exposure can prevent the emergence of psychosis-relevant phenotypes. However, whether BDZ exposure influences real-world clinical outcomes in individuals at clinical high risk for psychosis (CHR-P) is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Design<\/jats:title>\n                    <jats:p>This observational cohort study used electronic health record data from CHR-P individuals to investigate whether BDZ exposure (including hypnotics, eg, zopiclone) reduces the risk of developing psychosis and adverse clinical outcomes. Cox proportional-hazards models were employed in both the whole-unmatched sample, and a propensity score matched (PSM) subsample.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Results<\/jats:title>\n                    <jats:p>567 CHR-P individuals (306 male, mean[\u00b1SD] age\u2005=\u200522.3[\u00b14.9] years) were included after data cleaning. The BDZ-exposed (n\u2005=\u2005105) and BDZ-unexposed (n\u2005=\u2005462) groups differed on several demographic and clinical characteristics, including psychotic symptom severity. In the whole-unmatched sample, BDZ exposure was associated with increased risk of transition to psychosis (HR\u2005=\u20051.61; 95% CI: 1.03\u20132.52; P\u2005=\u2005.037), psychiatric hospital admission (HR\u2005=\u20051.93; 95% CI: 1.13\u20133.29; P\u2005=\u2005.017), home visit (HR\u2005=\u20051.64; 95% CI: 1.18\u20132.28; P\u2005=\u2005.004), and Accident and Emergency department attendance (HR\u2005=\u20051.88; 95% CI: 1.31\u20132.72; P\u2005&amp;lt;\u2005.001). However, after controlling for confounding-by-indication through PSM, BDZ exposure did not modulate the risk of any outcomes (all P\u2005&amp;gt;\u2005.05). In an analysis restricted to antipsychotic-na\u00efve individuals, BDZ exposure reduced the risk of transition to psychosis numerically, although this was not statistically significant (HR\u2005=\u20050.59; 95% CI: 0.32\u20131.08; P\u2005=\u2005.089).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BDZ exposure in CHR-P individuals was not associated with a reduction in the risk of psychosis transition or adverse clinical outcomes. Results in the whole-unmatched sample suggest BDZ prescription may be more likely in CHR-P individuals with higher symptom severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbae036","type":"journal-article","created":{"date-parts":[[2024,3,17]],"date-time":"2024-03-17T11:34:43Z","timestamp":1710675283000},"page":"446-457","source":"Crossref","is-referenced-by-count":5,"title":["Effects of Benzodiazepine Exposure on Real-World Clinical Outcomes in Individuals at Clinical High Risk for Psychosis"],"prefix":"10.1093","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6582-2545","authenticated-orcid":false,"given":"Nicholas R","family":"Livingston","sequence":"first","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"De Micheli","sequence":"additional","affiliation":[{"name":"Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]},{"name":"Outreach And Support in South London (OASIS) Service, South London and Maudsley NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1102-2566","authenticated-orcid":false,"given":"Robert A","family":"McCutcheon","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford , Oxford ,","place":["UK"]},{"name":"Oxford Health NHS Foundation Trust , Oxford ,","place":["UK"]},{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-3835","authenticated-orcid":false,"given":"Emma","family":"Butler","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwa","family":"Hamdan","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1864-5504","authenticated-orcid":false,"given":"Anthony A","family":"Grace","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]},{"name":"Department of Psychiatry, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]},{"name":"Department of Psychology, University of Pittsburgh , Pittsburgh, PA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4381-0532","authenticated-orcid":false,"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford , Oxford ,","place":["UK"]},{"name":"Oxford Health NHS Foundation Trust , Oxford ,","place":["UK"]},{"name":"National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre (BRC) , Oxford ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2939-064X","authenticated-orcid":false,"given":"Alice","family":"Egerton","sequence":"additional","affiliation":[{"name":"Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]},{"name":"National Institute of Health Research (NIHR), Maudsley Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3582-6788","authenticated-orcid":false,"given":"Paolo","family":"Fusar-Poli","sequence":"additional","affiliation":[{"name":"Early Psychosis: Interventions & Clinical-detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]},{"name":"Outreach And Support in South London (OASIS) Service, South London and Maudsley NHS Foundation Trust , London ,","place":["UK"]},{"name":"Department of Brain and Behavioural Sciences, University of Pavia , Pavia ,","place":["Italy"]},{"name":"National Institute of Health Research (NIHR), Maudsley Biomedical Research Centre (BRC), South London and Maudsley NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-066X","authenticated-orcid":false,"given":"Gemma","family":"Modinos","sequence":"additional","affiliation":[{"name":"Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King\u2019s College London , London ,","place":["UK"]},{"name":"MRC Centre for Neurodevelopmental Disorders, King\u2019s College London , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,4,3]]},"reference":[{"key":"2025031503085213100_CIT0001","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neubiorev.2010.07.001","article-title":"The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis","volume":"35","author":"Fett","year":"2011","journal-title":"Neurosci Biobehav Rev."},{"key":"2025031503085213100_CIT0002","doi-asserted-by":"publisher","first-page":"110315","DOI":"10.1016\/j.jpsychores.2020.110315","article-title":"The risk of physical multimorbidity in people with psychotic disorders: a systematic review and meta-analysis","volume":"140","author":"Rodrigues","year":"2021","journal-title":"J Psychosom Res."},{"issue":"2","key":"2025031503085213100_CIT0003","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/wps.20959","article-title":"The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics","volume":"21","author":"Fusar-Poli","year":"2022","journal-title":"World Psychiatry."},{"key":"2025031503085213100_CIT0004","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/schbul\/sbw158","article-title":"The clinical high-risk state for psychosis (CHR-P), version II","volume":"43","author":"Fusar-Poli","year":"2017","journal-title":"Schizophr Bull."},{"key":"2025031503085213100_CIT0005","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamapsychiatry.2013.269","article-title":"The psychosis high-risk state: a comprehensive state-of-the-art review","volume":"70","author":"Fusar-Poli","year":"2013","journal-title":"Arch Gen Psychiatry."},{"issue":"9","key":"2025031503085213100_CIT0006","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1001\/jamapsychiatry.2021.0830","article-title":"Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis","volume":"78","author":"Salazar de Pablo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"5","key":"2025031503085213100_CIT0007","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jcpp.13322","article-title":"Annual Research Review: prevention of psychosis in adolescents - systematic review and meta-analysis of advances in detection, prognosis and intervention","volume":"62","author":"Catalan","year":"2021","journal-title":"J Child Psychol Psychiatry."},{"key":"2025031503085213100_CIT0008","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1017\/S2045796021000639","article-title":"Clinical outcomes in individuals at clinical high risk of psychosis who do not transition to psychosis: a meta-analysis","volume":"31","author":"de Pablo","year":"2022","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"3","key":"2025031503085213100_CIT0009","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1192\/bjp.bp.114.157115","article-title":"Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis","volume":"207","author":"Fusar-Poli","year":"2015","journal-title":"Br J Psychiatry."},{"issue":"1","key":"2025031503085213100_CIT0010","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41398-022-01961-7","article-title":"Examining the variability of neurocognitive functioning in individuals at clinical high risk for psychosis: a meta-analysis","volume":"12","author":"Catalan","year":"2022","journal-title":"Transl Psychiatry."},{"issue":"8","key":"2025031503085213100_CIT0011","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jamapsychiatry.2021.1290","article-title":"Neurocognitive functioning in individuals at clinical high risk for psychosis: a systematic review and meta-analysis","volume":"78","author":"Catalan","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2025031503085213100_CIT0012","doi-asserted-by":"publisher","first-page":"100578","DOI":"10.1016\/j.eclinm.2020.100578","article-title":"Real-world long-term outcomes in individuals at clinical risk for psychosis: the case for extending duration of care","volume":"28","author":"Fusar-Poli","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2025031503085213100_CIT0013","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.schres.2019.12.002","article-title":"Predictive validity of conversion from the clinical high risk syndrome to frank psychosis","volume":"216","author":"Yoviene Sykes","year":"2020","journal-title":"Schizophr Res."},{"key":"2025031503085213100_CIT0014","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/wps.20526","article-title":"Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis","volume":"17","author":"Davies","year":"2018","journal-title":"World Psychiatry"},{"issue":"3","key":"2025031503085213100_CIT0015","doi-asserted-by":"publisher","first-page":"9326","DOI":"10.4088\/JCP.17r12053","article-title":"Interventions and transition in youth at risk of psychosis: a systematic review and meta-analyses","volume":"81","author":"Devoe","year":"2020","journal-title":"J Clin Psychiatry."},{"key":"2025031503085213100_CIT0016","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/schbul\/sbad029","article-title":"Prevention of first-episode psychosis in people at clinical high risk: a randomized controlled, multicentre trial comparing cognitive-behavioral therapy and clinical management plus low-dose aripiprazole or placebo (PREVENT)","volume":"49","author":"Bechdolf","year":"2023","journal-title":"Schizophr Bull."},{"key":"2025031503085213100_CIT0017","doi-asserted-by":"publisher","first-page":"102005","DOI":"10.1016\/j.cpr.2021.102005","article-title":"Preventive interventions for individuals at ultra high risk for psychosis: an updated and extended meta-analysis","volume":"86","author":"Mei","year":"2021","journal-title":"Clin Psychol Rev."},{"key":"2025031503085213100_CIT0018","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.tins.2018.12.004","article-title":"Schizophrenia, dopamine and the striatum: from biology to symptoms","volume":"42","author":"McCutcheon","year":"2019","journal-title":"Trends Neurosci."},{"issue":"9","key":"2025031503085213100_CIT0019","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.tips.2011.05.001","article-title":"Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia","volume":"32","author":"Lodge","year":"2011","journal-title":"Trends Pharmacol Sci."},{"key":"2025031503085213100_CIT0020","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.schres.2014.09.041","article-title":"GABAergic mechanisms of hippocampal hyperactivity in schizophrenia","volume":"167","author":"Heckers","year":"2015","journal-title":"Schizophr Res."},{"key":"2025031503085213100_CIT0021","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nrn.2016.57","article-title":"Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression","volume":"17","author":"Grace","year":"2016","journal-title":"Nat Rev Neurosci."},{"key":"2025031503085213100_CIT0022","doi-asserted-by":"publisher","first-page":"S2451-9022(23)00339","DOI":"10.1016\/j.bpsc.2023.12.002","article-title":"The Trajectory of Prefrontal GABA levels in initially antipsychotic-na\u00efve patients with psychosis during two years treatment and associations with striatal cerebral blood flow and outcome","author":"Bojesen","year":"2023","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"3","key":"2025031503085213100_CIT0023","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.bpsgos.2022.05.004","article-title":"Dopamine synthesis capacity and GABA and glutamate levels separate antipsychotic-na\u00efve patients with first-episode psychosis from healthy control subjects in a multimodal prediction model","volume":"3","author":"Sigvard","year":"2023","journal-title":"Biol Psychiatry Glob Open Sci."},{"key":"2025031503085213100_CIT0024","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/npp.2016.42","article-title":"Amygdala hyperactivity in MAM model of schizophrenia is normalized by peripubertal diazepam administration","volume":"41","author":"Du","year":"2016","journal-title":"Neuropsychopharmacology."},{"key":"2025031503085213100_CIT0025","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1038\/npp.2013.101","article-title":"Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia","volume":"38","author":"Du","year":"2013","journal-title":"Neuropsychopharmacology."},{"key":"2025031503085213100_CIT0026","doi-asserted-by":"publisher","first-page":"pyw065","DOI":"10.1093\/ijnp\/pyw065","article-title":"Loss of parvalbumin in the hippocampus of MAM schizophrenia model rats is attenuated by peripubertal diazepam","volume":"19","author":"Du","year":"2016","journal-title":"Int J Neuropsychopharmacol."},{"issue":"2","key":"2025031503085213100_CIT0027","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1176\/ajp.156.2.299","article-title":"Diazepam treatment of early signs of exacerbation in schizophrenia","volume":"156","author":"Carpenter","year":"1999","journal-title":"Am J Psychiatry."},{"key":"2025031503085213100_CIT0028","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/schbul\/sbt236","article-title":"Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia","volume":"40","author":"Gill","year":"2014","journal-title":"Schizophr Bull."},{"key":"2025031503085213100_CIT0029","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1038\/npp.2011.76","article-title":"A novel \u03b15GABA a r-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia","volume":"36","author":"Gill","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"2025031503085213100_CIT0030","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euroneuro.2020.08.002","article-title":"Outreach and support in South-London (OASIS) 2001-2020: twenty years of early detection, prognosis and preventive care for young people at risk of psychosis","volume":"39","author":"Fusar-Poli","year":"2020","journal-title":"Eur Neuropsychopharmacol."},{"issue":"3","key":"2025031503085213100_CIT0031","doi-asserted-by":"publisher","first-page":"e008721","DOI":"10.1136\/bmjopen-2015-008721","article-title":"Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource","volume":"6","author":"Perera","year":"2016","journal-title":"BMJ Open"},{"issue":"2","key":"2025031503085213100_CIT0032","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0301-0082(02)00013-8","article-title":"Drug interactions at GABAA receptors","volume":"67","author":"Korpi","year":"2002","journal-title":"Prog Neurobiol."},{"issue":"1","key":"2025031503085213100_CIT0033","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1017\/S0033291723003203","article-title":"Letter to the Editor on \u2018Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis.\u2019","volume":"54","author":"Livingston","year":"2024","journal-title":"Psychol Med."},{"key":"2025031503085213100_CIT0034","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0033291723002180","article-title":"Baseline benzodiazepine exposure is associated with greater risk of transition in clinical high-risk for psychosis (CHR-P): a meta-analysis","author":"Raballo","year":"2023","journal-title":"Psychol Med."},{"key":"2025031503085213100_CIT0035","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"issue":"10","key":"2025031503085213100_CIT0036","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2016.15070890","article-title":"An individualized risk calculator for research in prodromal psychosis","volume":"173","author":"Cannon","year":"2016","journal-title":"Am J Psychiatry."},{"key":"2025031503085213100_CIT0037","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/archgenpsychiatry.2007.3","article-title":"Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America","volume":"65","author":"Cannon","year":"2008","journal-title":"Arch Gen Psychiatry."},{"key":"2025031503085213100_CIT0038","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1111\/j.1440-1614.2005.01714.x","article-title":"Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States","volume":"39","author":"Yung","year":"2005","journal-title":"Aust N Z J Psychiatry."},{"issue":"1","key":"2025031503085213100_CIT0039","doi-asserted-by":"publisher","first-page":"101215","DOI":"10.1016\/j.xpro.2022.101215","article-title":"Use of prepubertal environment enrichment to prevent dopamine dysregulation in a neurodevelopmental rat model of schizophrenia risk","volume":"3","author":"Zhu","year":"2022","journal-title":"STAR Protoc"},{"key":"2025031503085213100_CIT0040","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fpsyt.2018.00187","article-title":"Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis","volume":"9","author":"Davies","year":"2018","journal-title":"Front Psychiatry."},{"key":"2025031503085213100_CIT0041","doi-asserted-by":"publisher","first-page":"976035","DOI":"10.3389\/fpsyt.2022.976035","article-title":"Timing of antipsychotics and benzodiazepine initiation during a first episode of psychosis impacts clinical outcomes: electronic health record cohort study","volume":"13","author":"Arribas","year":"2022","journal-title":"Front Psychiatry."},{"issue":"1","key":"2025031503085213100_CIT0042","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/JCP.0000000000001497","article-title":"Use of benzodiazepines and antipsychotic drugs are inversely associated with acute readmission risk in schizophrenia","volume":"42","author":"Str\u00f8mme","year":"2022","journal-title":"J Clin Psychopharmacol."},{"key":"2025031503085213100_CIT0043","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.2147\/NDT.S118759","article-title":"Association between the high-dose use of benzodiazepines and rehospitalization in patients with schizophrenia: a 2-year naturalistic study","volume":"12","author":"Takita","year":"2016","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"9","key":"2025031503085213100_CIT0044","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.euroneuro.2013.03.001","article-title":"Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and cochrane review of randomized controlled trials","volume":"23","author":"Dold","year":"2013","journal-title":"Eur Neuropsychopharmacol."},{"issue":"9","key":"2025031503085213100_CIT0045","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1592\/phco.24.13.1177.38089","article-title":"Paradoxical reactions to benzodiazepines: literature review and treatment options","volume":"24","author":"Mancuso","year":"2004","journal-title":"Pharmacotherapy."},{"issue":"3","key":"2025031503085213100_CIT0046","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1001\/jamapsychiatry.2022.4599","article-title":"sleep abnormalities in different clinical stages of psychosis: a systematic review and meta-analysis","volume":"80","author":"Bagautdinova","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"2025031503085213100_CIT0047","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/schbul\/sbab104","article-title":"Sleep disturbance in individuals at clinical high risk for psychosis","volume":"48","author":"Zaks","year":"2022","journal-title":"Schizophr Bull."},{"issue":"1\u20133","key":"2025031503085213100_CIT0048","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.schres.2013.09.015","article-title":"Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis","volume":"151","author":"Lunsford-Avery","year":"2013","journal-title":"Schizophr Res."},{"issue":"3","key":"2025031503085213100_CIT0049","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2009.206","article-title":"Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study","volume":"67","author":"Ruhrmann","year":"2010","journal-title":"Arch Gen Psychiatry."},{"issue":"10","key":"2025031503085213100_CIT0050","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1176\/appi.ajp.2020.20070968","article-title":"Sleep abnormalities in schizophrenia: state of the art and next steps","volume":"178","author":"Ferrarelli","year":"2021","journal-title":"Am J Psychiatry."},{"issue":"2","key":"2025031503085213100_CIT0051","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1017\/S0033291719003234","article-title":"Change in incidence rates for psychosis in different ethnic groups in south London: findings from the Clinical Record Interactive Search-First Episode Psychosis (CRIS-FEP) study","volume":"51","author":"Oduola","year":"2021","journal-title":"Psychol Med."}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/2\/446\/57144477\/sbae036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/2\/446\/57144477\/sbae036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T23:09:23Z","timestamp":1741993763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/51\/2\/446\/7639579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,3]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4,3]]},"published-print":{"date-parts":[[2025,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbae036","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.15.23294108","asserted-by":"object"}]},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"value":"0586-7614","type":"print"},{"value":"1745-1701","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,4,3]]}}}